Abbott Cardiovascular Systems, Inc.

Efemoral Medical Inc.

Abbott Laboratories Corporation

Gregory Orr

John E Papp

Lewis B Schwartz

Dudley Shelton Jayasinghe

Mikael Trollsas

Michael H Ngo

Hung T Nguyen

Yongjin Xie

Joshua Smith

Christopher Haig

Yu-Chun Ku

Jayson Delos Santos

Ron Farnbach

Kent C B Stalker

Winnette S McIntosh

A multi-element, bioresorbable, vascular stent may be used to maintain or enhance patency of a blood vessel. The stent may be used in peripheral blood vessels, which may be long and/or tortuous. By using multiple, separate stent elements that are balloon expandable, the multi-element stent may be stronger than a traditional self-expanding stent but may also be more flexible, due to its multiple-element configuration, than a traditional balloon-expandable stent. Thus, the multi-element, bioresorbable, vascular stent described herein may be particularly advantageous for treating long lesions in tortuous peripheral blood vessels.

Multi-element bioresorbable intravascular stent

Methods for making scaffolds for delivery via a balloon catheter are described. The scaffold, after being deployed by the balloon, provides a crush recovery of about 90% after the diameter of the scaffold has been pinched or crushed by 50%. The scaffold structure has patterns that include an asymmetric or symmetric closed cell, and links connecting such closed cells.

Processes for making crush recoverable polymer scaffolds

A drug eluting stent can include a stent body having a polymeric coating with a lipophilic and/or hydrophilic element. A drug that has a bioactivity that inhibits cell proliferation can be disposed in the polymeric coating. The drug can be present in the polymer at an amount greater than or equal to about 150 &#x3bc;g/cm. The polymeric coating and drug are configured to cooperate so as to form a diffusion pathway with tissue when the stent is disposed in a body lumen such that the drug preferentially diffuses into the tissue over a body fluid passing through the body lumen such that a maximum systemic blood concentration of the drug is less than about 40 ng/ml.

Methods of treatment with drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations

Growing community of inventors

Escondido, CA, United States of America

Gregory Orr